{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T10:18:29Z","timestamp":1794910709382,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ahjo.2026.100913","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:02:32Z","timestamp":1790265752000},"page":"100913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Public availability of trial-design and clinical-context information in contemporary lipoprotein(a)-targeted cardiovascular trials: A cross-sectional meta-research study"],"prefix":"10.1016","volume":"71","author":[{"given":"Samuel","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Yow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ahjo.2026.100913_bb0005","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"European atherosclerosis society consensus panel. Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ahjo.2026.100913_bb0010","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100913_bb0015","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"39","key":"10.1016\/j.ahjo.2026.100913_bb0020","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100913_bb0025","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 National Lipid Association scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J. Clin. Lipidol."},{"issue":"4","key":"10.1016\/j.ahjo.2026.100913_bb0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein(a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100913_bb0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ahjo.2026.100913_bb0040","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ahjo.2026.100913_bb0045","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ahjo.2026.100913_bb0050","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2024.4504","article-title":"Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial","volume":"331","author":"Nissen","year":"2024","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ahjo.2026.100913_bb0055","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran-a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ahjo.2026.100913_bb0060","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ahjo.2026.100913_bb0065","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.ahjo.2026.100913_bb0070","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies: JACC focus seminar 2\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100913_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of cardiovascular events and lipoproteiN(a) reduction-DOSE finding study","volume":"251","author":"O\u2019Donoghue","year":"2022","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ahjo.2026.100913_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with cardiovascular disease and elevated lipoprotein(a)","volume":"283","author":"Cho","year":"2025","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100913_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11883-024-01252-0","article-title":"Lp(a): a rapidly evolving therapeutic landscape","volume":"27","author":"Anchouche","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100913_bb0090","doi-asserted-by":"crossref","DOI":"10.1007\/s12170-025-00759-8","article-title":"Current clinical trials for treating elevated lipoprotein(a)","volume":"19","author":"De Los Reyes","year":"2025","journal-title":"Curr. Cardiovasc. Risk Rep."},{"key":"10.1016\/j.ahjo.2026.100913_bb0095","article-title":"How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider","volume":"361","author":"Tse","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ahjo.2026.100913_bb0100","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","article-title":"The ClinicalTrials.gov results database-update and key issues","volume":"364","author":"Zarin","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100913_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033677","article-title":"The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty","volume":"7","author":"Tasneem","year":"2012","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.ahjo.2026.100913_bb0110","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/17512433.2020.1787832","article-title":"Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review","volume":"13","author":"van Bruggen","year":"2020","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.ahjo.2026.100913_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-017177","article-title":"Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps","volume":"9","author":"Jeyakumar","year":"2024","journal-title":"BMJ Glob. Health"},{"issue":"9596","key":"10.1016\/j.ahjo.2026.100913_bb0120","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ahjo.2026.100913_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The reporting of studies conducted using observational routinely collected health data statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100913_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.ahjo.2026.100913_bb0135","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ahjo.2026.100913_bb0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"22","key":"10.1016\/j.ahjo.2026.100913_bb0145","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ahjo.2026.100913_bb0150","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/jama.2022.21243","article-title":"Guidelines for reporting outcomes in trial protocols: the SPIRIT-outcomes 2022 extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"issue":"33","key":"10.1016\/j.ahjo.2026.100913_bb0155","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226002028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226002028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:36:00Z","timestamp":1794908160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602226002028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"alternative-id":["S2666602226002028"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100913","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Public availability of trial-design and clinical-context information in contemporary lipoprotein(a)-targeted cardiovascular trials: A cross-sectional meta-research study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100913"}}